Acura Pharmaceuticals, Inc. has amended its Secured Promissory Note with Abuse Deterrent Pharma, LLC.
The amendment includes the addition of Loan #39 through Loan #49, expanding the original note's scope.
Robert A. Seiser, Senior VP & CFO, signed the amended schedule on December 12, 2025.
The addition of loans suggests strategic financial planning and potential expansion opportunities for Acura Pharmaceuticals.
Amended Promissory Note
The inclusion of Loan #39 through #49 in the amended promissory note enhances Acura Pharmaceuticals' financial flexibility and potentially supports growth initiatives.
Signatory
Robert A. Seiser, Senior VP & CFO, played a critical role in authorizing the amendment, underlining internal support for the financial adjustment.
- The amendment reflects Acura Pharmaceuticals' active financial management and potential strategic initiatives to drive growth and enhance financial stability.
- The expanded loan schedule may contribute to Acura's long-term financial strength by providing additional capital for investments and operational activities.
Acura Pharmaceuticals' recent amendment to the loan schedule underlines a strategic approach to financial management and growth. The expanded loan portfolio signifies a proactive stance towards seizing growth opportunities and bolstering financial resilience. With Robert A. Seiser's leadership, Acura Pharmaceuticals seems poised for sustained progress in the pharmaceutical sector.